R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv 03022, Ukraine.
National Institute of Cancer, Ministry of Health of Ukraine, Kyiv 03022, Ukraine.
Exp Oncol. 2022 Aug;44(2):148-154. doi: 10.32471/exp-oncology.2312-8852.vol-44-no-2.17758.
Prostate cancer (PCa) is one of the most common malignancies in older men. The study of tissue markers of PCa can provide information about the state of proliferation and apoptosis in tumors, the susceptibility of tumor cells to metastasis and the mechanisms of resistance to therapy, which, in turn, can help predict the course of the disease and develop personalized treatment. Polyamines (PAs) spermine, spermidine, putrescine are of particular interest in terms of PCa tissue markers.
To investigate the levels of basic and acetylated forms of PAs in the postoperative samples of malignant and benign tumors of the human prostate and evaluate the possibility of their use for differential diagnosis and assessment of the PCa aggressiveness.
57 postoperative tumor samples from patients with prostate adenocarcinoma of different Gleason score (GS) and clinical stage (T1-T4) and 20 samples of tumors from patients with benign prostate hyperplasia (BPH) were studied. The content of PAs was determined by high performance liquid chromatography.
Among the studied PAs, the most significant difference between PCa and BPH was observed for spermine (Spm). The level of Spm in PCa samples was 16 times lower than in BPH samples (p < 0.01). We did not find a significant dependence of PAs levels, including Spm, on the clinical stage. The association between the Spm level and the GS was established. The indolent (GS6) tumors were characterized by the highest Spm level while in the most aggressive (GS9 and GS10) tumors Spm content was the lowest.
A sharp decrease in Spm levels is probably a characteristic feature of prostate malignant tumors. The obtained results indicate an association of Spm levels in tumors with the GS. This may indicate Spm involvement in the formation of the aggressiveness of PCa. The results of the study can be further used for differential diagnosis of prostate tumors and for assessing the aggressiveness of PCa.
前列腺癌（PCa）是老年男性中最常见的恶性肿瘤之一。研究 PCa 的组织标志物可以提供有关肿瘤增殖和凋亡状态、肿瘤细胞转移易感性以及治疗耐药机制的信息，这反过来又可以帮助预测疾病进程并制定个性化治疗方案。多胺（PAs）精脒、精胺、腐胺在 PCa 组织标志物方面特别引人关注。
研究人前列腺恶性和良性肿瘤术后样本中基本和乙酰化形式多胺（PAs）的水平，并评估其用于鉴别诊断和评估 PCa 侵袭性的可能性。
研究了 57 例不同 Gleason 评分（GS）和临床分期（T1-T4）的前列腺腺癌患者和 20 例良性前列腺增生（BPH）患者的术后肿瘤样本。通过高效液相色谱法测定 PAs 的含量。
在所研究的 PAs 中，PCa 与 BPH 之间最显著的差异是精脒（Spm）。PCa 样本中的 Spm 水平比 BPH 样本低 16 倍（p<0.01）。我们没有发现 PAs 水平（包括 Spm）与临床分期之间存在显著的相关性。建立了 Spm 水平与 GS 的关联。惰性（GS6）肿瘤的 Spm 水平最高，而最具侵袭性（GS9 和 GS10）肿瘤的 Spm 含量最低。
Spm 水平的急剧下降可能是前列腺恶性肿瘤的特征。所得结果表明肿瘤中 Spm 水平与 GS 之间存在关联。这可能表明 Spm 参与了 PCa 侵袭性的形成。研究结果可进一步用于前列腺肿瘤的鉴别诊断和评估 PCa 的侵袭性。
